GT Biopharma shareholders approve reverse stock split and incentive plan amendments

GT Biopharma, Inc.

Approved reverse stock split (1-for-10 to 1-for-30) and cut authorized common to 25M, preferred to 1.5M.
Elected directors Breen, Casamento, Kramer, Mun-Gavin; votes ranged 6.7M-8.1M for.
Ratified Weinberg & Company as independent auditor for FY2026 (22.7M for).
Approved non-binding executive compensation (6.1M for) and 2022 Plan amendments adding 3.5M shares and evergreen provision.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.